SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $976,827,960 |
| Positions | 77 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| MBX BIOSCIENCES INC | MBX | COM | $44,169,550 | 800,173 |
| ELI LILLY & CO | LLY | COM | $41,980,050 | 35,000 |
| CVS HEALTH CORP | CVS | COM | $40,530,779 | 391,791 |
| DEXCOM INC | DXCM | COM | $36,016,557 | 534,767 |
| PTC THERAPEUTICS INC | PTCT | COM | $35,539,315 | 435,691 |
| ARCUS BIOSCIENCES INC | RCUS | COM | $28,340,971 | 919,266 |
| STRUCTURE THERAPEUTICS INC | GPCR | SPONSORED ADS | $26,065,426 | 485,661 |
| VIRIDIAN THERAPEUTICS INC | VRDN | COM | $25,306,071 | 1,377,576 |
| AGIOS PHARMACEUTICALS INC | AGIO | COM | $24,828,297 | 669,046 |
| INHIBRX BIOSCIENCES INC | INBX | COM | $24,346,013 | 256,950 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.